Comorbidities, treatment, and pathophysiology in restless legs syndrome

Claudia Trenkwalder, Richard Allen, Birgit Högl, Stefan Clemens, Stephanie Patton, Barbara Schormair, Juliane Winkelmann

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Restless legs syndrome, also known as Willis-Ekbom disease, is a common neurological condition whose manifestation is affected by complex environmental and genetic interactions. Restless legs syndrome can occur on its own, mostly at a young age, or with comorbidities such as cardiovascular disease, diabetes, and arterial hypertension, making it a difficult condition to properly diagnose. However, the concept of restless legs syndrome as being two entities, primary or secondary to another condition, has been challenged with genetic data providing further insight into the pathophysiology of the condition. Although dopaminergic treatment was formerly the first-line therapy, prolonged use can result in a serious worsening of symptoms known as augmentation. Clinical studies on pregabalin, gabapentin enacarbil, oxycodone–naloxone, and iron preparations have provided new treatment options, but most patients still report inadequate long-term management of symptoms. Studies of the hypoxic pathway activation and iron deficiency have provided valuable information about the pathophysiology of restless legs syndrome that should now be translated into new, more effective treatments for restless legs syndrome.

Original languageEnglish (US)
Pages (from-to)994-1005
Number of pages12
JournalThe Lancet Neurology
Volume17
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Restless Legs Syndrome
Comorbidity
Therapeutics
Iron
Cardiovascular Diseases
Hypertension

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Trenkwalder, C., Allen, R., Högl, B., Clemens, S., Patton, S., Schormair, B., & Winkelmann, J. (2018). Comorbidities, treatment, and pathophysiology in restless legs syndrome. The Lancet Neurology, 17(11), 994-1005. https://doi.org/10.1016/S1474-4422(18)30311-9
Trenkwalder, Claudia ; Allen, Richard ; Högl, Birgit ; Clemens, Stefan ; Patton, Stephanie ; Schormair, Barbara ; Winkelmann, Juliane. / Comorbidities, treatment, and pathophysiology in restless legs syndrome. In: The Lancet Neurology. 2018 ; Vol. 17, No. 11. pp. 994-1005.
@article{73131e8bdfa245d5aa7d177176687820,
title = "Comorbidities, treatment, and pathophysiology in restless legs syndrome",
abstract = "Restless legs syndrome, also known as Willis-Ekbom disease, is a common neurological condition whose manifestation is affected by complex environmental and genetic interactions. Restless legs syndrome can occur on its own, mostly at a young age, or with comorbidities such as cardiovascular disease, diabetes, and arterial hypertension, making it a difficult condition to properly diagnose. However, the concept of restless legs syndrome as being two entities, primary or secondary to another condition, has been challenged with genetic data providing further insight into the pathophysiology of the condition. Although dopaminergic treatment was formerly the first-line therapy, prolonged use can result in a serious worsening of symptoms known as augmentation. Clinical studies on pregabalin, gabapentin enacarbil, oxycodone–naloxone, and iron preparations have provided new treatment options, but most patients still report inadequate long-term management of symptoms. Studies of the hypoxic pathway activation and iron deficiency have provided valuable information about the pathophysiology of restless legs syndrome that should now be translated into new, more effective treatments for restless legs syndrome.",
author = "Claudia Trenkwalder and Richard Allen and Birgit H{\"o}gl and Stefan Clemens and Stephanie Patton and Barbara Schormair and Juliane Winkelmann",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/S1474-4422(18)30311-9",
language = "English (US)",
volume = "17",
pages = "994--1005",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "11",

}

Trenkwalder, C, Allen, R, Högl, B, Clemens, S, Patton, S, Schormair, B & Winkelmann, J 2018, 'Comorbidities, treatment, and pathophysiology in restless legs syndrome', The Lancet Neurology, vol. 17, no. 11, pp. 994-1005. https://doi.org/10.1016/S1474-4422(18)30311-9

Comorbidities, treatment, and pathophysiology in restless legs syndrome. / Trenkwalder, Claudia; Allen, Richard; Högl, Birgit; Clemens, Stefan; Patton, Stephanie; Schormair, Barbara; Winkelmann, Juliane.

In: The Lancet Neurology, Vol. 17, No. 11, 01.11.2018, p. 994-1005.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Comorbidities, treatment, and pathophysiology in restless legs syndrome

AU - Trenkwalder, Claudia

AU - Allen, Richard

AU - Högl, Birgit

AU - Clemens, Stefan

AU - Patton, Stephanie

AU - Schormair, Barbara

AU - Winkelmann, Juliane

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Restless legs syndrome, also known as Willis-Ekbom disease, is a common neurological condition whose manifestation is affected by complex environmental and genetic interactions. Restless legs syndrome can occur on its own, mostly at a young age, or with comorbidities such as cardiovascular disease, diabetes, and arterial hypertension, making it a difficult condition to properly diagnose. However, the concept of restless legs syndrome as being two entities, primary or secondary to another condition, has been challenged with genetic data providing further insight into the pathophysiology of the condition. Although dopaminergic treatment was formerly the first-line therapy, prolonged use can result in a serious worsening of symptoms known as augmentation. Clinical studies on pregabalin, gabapentin enacarbil, oxycodone–naloxone, and iron preparations have provided new treatment options, but most patients still report inadequate long-term management of symptoms. Studies of the hypoxic pathway activation and iron deficiency have provided valuable information about the pathophysiology of restless legs syndrome that should now be translated into new, more effective treatments for restless legs syndrome.

AB - Restless legs syndrome, also known as Willis-Ekbom disease, is a common neurological condition whose manifestation is affected by complex environmental and genetic interactions. Restless legs syndrome can occur on its own, mostly at a young age, or with comorbidities such as cardiovascular disease, diabetes, and arterial hypertension, making it a difficult condition to properly diagnose. However, the concept of restless legs syndrome as being two entities, primary or secondary to another condition, has been challenged with genetic data providing further insight into the pathophysiology of the condition. Although dopaminergic treatment was formerly the first-line therapy, prolonged use can result in a serious worsening of symptoms known as augmentation. Clinical studies on pregabalin, gabapentin enacarbil, oxycodone–naloxone, and iron preparations have provided new treatment options, but most patients still report inadequate long-term management of symptoms. Studies of the hypoxic pathway activation and iron deficiency have provided valuable information about the pathophysiology of restless legs syndrome that should now be translated into new, more effective treatments for restless legs syndrome.

UR - http://www.scopus.com/inward/record.url?scp=85055027632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055027632&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(18)30311-9

DO - 10.1016/S1474-4422(18)30311-9

M3 - Review article

VL - 17

SP - 994

EP - 1005

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 11

ER -